Solventum Corporation $SOLV Shares Newly Acquired by Westwind Capital

Key Points

• Westwind Capital acquired 18,663 Solventum shares in the third quarter, valued at approximately $1.645 million. Several other institutional investors also increased or initiated positions in the healthcare company.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $92.80. Recent targets range from $81 to $113.
• Solventum reported quarterly EPS of $2.55, exceeding estimates of $1.91, while revenue reached $2.21 billion and grew 2.2% year over year. The stock recently traded at $86.44, with a market capitalization of approximately $14.71 billion.

Westwind Capital acquired a new position in Solventum Corporation (NYSE:SOLV - Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 18,663 shares of the company's stock, valued at approximately $1,645,000.

Several other institutional investors have also recently made changes to their positions in SOLV. Clearstead Trust LLC lifted its holdings in Solventum by 61.0% in the 1st quarter. Clearstead Trust LLC now owns 396 shares of the company's stock worth $26,000 after purchasing an additional 150 shares in the last quarter. MV Capital Management Inc. purchased a new stake in Solventum during the 4th quarter valued at approximately $34,000. Caitong International Asset Management Co. Ltd raised its position in shares of Solventum by 80.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 429 shares of the company's stock valued at $34,000 after buying an additional 191 shares during the last quarter. JNBA Financial Advisors raised its position in shares of Solventum by 71.9% during the second quarter. JNBA Financial Advisors now owns 507 shares of the company's stock valued at $39,000 after buying an additional 212 shares during the last quarter. Finally, Ameritas Advisory Services LLC purchased a new position in shares of Solventum in the second quarter worth $47,000.

Wall Street Analyst Weigh In

SOLV has been the topic of several research analyst reports. BMO Capital Markets assumed coverage on shares of Solventum in a research note on Wednesday, July 8th. They issued a "market perform" rating and a $81.00 price target on the stock. Mizuho set a $113.00 target price on Solventum in a research report on Thursday, August 6th. UBS Group raised their price target on Solventum from $95.00 to $101.00 and gave the company a "buy" rating in a report on Thursday, August 6th. Benchmark reaffirmed a "buy" rating on shares of Solventum in a research note on Thursday. Finally, Piper Sandler upped their price objective on Solventum from $92.00 to $105.00 and gave the stock an "overweight" rating in a report on Thursday, August 6th. Ten analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $92.80.

Solventum Trading Up 0.6%

NYSE SOLV traded up $0.56 during trading hours on Thursday, hitting $86.44. 1,286,542 shares of the company were exchanged, compared to its average volume of 1,313,969. Solventum Corporation has a 52 week low of $62.38 and a 52 week high of $94.16. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 1.00. The stock has a 50-day moving average price of $88.54 and a 200 day moving average price of $79.07. The stock has a market cap of $14.71 billion, a PE ratio of 10.57, a price-to-earnings-growth ratio of 1.36 and a beta of 0.63.

Solventum (NYSE:SOLV - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $2.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $0.64. The business had revenue of $2.21 billion during the quarter, compared to analyst estimates of $2.15 billion. Solventum had a return on equity of 25.09% and a net margin of 17.26%.The company's revenue for the quarter was up 2.2% on a year-over-year basis. During the same period last year, the company earned $1.69 EPS. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. Analysts forecast that Solventum Corporation will post 7.22 earnings per share for the current fiscal year.

About Solventum

Solventum Corporation NYSE: SOLV is a global healthcare company that develops products, technologies and services designed to support clinical care, healthcare operations and patient outcomes. The company serves healthcare providers, dental professionals, laboratories, manufacturers and other organizations.

Solventum's portfolio includes medical and surgical products such as wound-care systems, surgical drapes, sterilization and infection-prevention solutions, and patient-monitoring or fixation products.

Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Corporation (NYSE:SOLV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.